Symbols / ABCL $3.57 +1.42%
ABCL Chart
About
AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; AbbVie Inc.; and partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 1.08B |
| Enterprise Value | 691.67M | Income | -146.41M | Sales | 75.13M |
| Book/sh | 3.22 | Cash/sh | 1.76 | Dividend Yield | — |
| Payout | 0.00% | Employees | 562 | IPO | — |
| P/E | — | Forward P/E | -4.64 | PEG | — |
| P/S | 14.41 | P/B | 1.11 | P/C | — |
| EV/EBITDA | -3.55 | EV/Sales | 9.21 | Quick Ratio | 10.07 |
| Current Ratio | 11.32 | Debt/Eq | 14.81 | LT Debt/Eq | — |
| EPS (ttm) | -0.49 | EPS next Y | -0.77 | EPS Growth | — |
| Revenue Growth | 7.88% | Earnings | 2026-05-07 | ROA | -9.99% |
| ROE | -14.47% | ROIC | — | Gross Margin | -148.68% |
| Oper. Margin | -63.72% | Profit Margin | -194.88% | Shs Outstand | 303.16M |
| Shs Float | 207.89M | Short Float | 21.76% | Short Ratio | 10.59 |
| Short Interest | — | 52W High | 6.51 | 52W Low | 1.89 |
| Beta | 0.87 | Avg Volume | 4.25M | Volume | 2.15M |
| Target Price | $9.17 | Recom | Strong_buy | Prev Close | $3.52 |
| Price | $3.57 | Change | 1.42% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$9.17
Mean price target
2. Current target
$3.57
Latest analyst target
3. DCF / Fair value
$-10.45
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$3.57
Low
$7.00
High
$12.00
Mean
$9.17
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-11-07 | down | Leerink Partners | Outperform → Market Perform | $4 |
| 2025-08-08 | main | Stifel | Buy → Buy | $7 |
| 2025-07-14 | main | Keybanc | Overweight → Overweight | $10 |
| 2025-05-16 | main | Truist Securities | Buy → Buy | $10 |
| 2025-05-09 | main | Stifel | Buy → Buy | $8 |
| 2025-04-16 | main | Keybanc | Overweight → Overweight | $5 |
| 2025-03-03 | reit | Benchmark | Hold → Hold | — |
| 2025-02-28 | main | Stifel | Buy → Buy | $10 |
| 2025-01-08 | main | Keybanc | Overweight → Overweight | $4 |
| 2024-11-05 | reit | Benchmark | — → Hold | — |
| 2024-11-05 | reit | Stifel | Buy → Buy | $12 |
| 2024-08-20 | down | Benchmark | Buy → Hold | — |
| 2024-07-11 | main | Keybanc | Overweight → Overweight | $5 |
| 2024-05-08 | main | Keybanc | Overweight → Overweight | $7 |
| 2024-02-22 | up | Benchmark | Hold → Buy | — |
| 2024-02-21 | main | Stifel | Buy → Buy | $17 |
| 2023-12-05 | init | Keybanc | — → Overweight | $6 |
| 2023-08-31 | main | Benchmark | Buy → Buy | $12 |
| 2023-08-04 | main | Goldman Sachs | Buy → Buy | $24 |
| 2023-05-05 | main | Credit Suisse | — → Outperform | $28 |
- A Look At AbCellera Biologics (ABCL) Valuation After Annual Earnings Reveal Higher Revenue And A Narrower Net Loss - simplywall.st ue, 10 Mar 2026 09
- $ABCL stock is down 4% today. Here's what we see in our data. - Quiver Quantitative ue, 03 Mar 2026 14
- AbCellera Biologics Inc. (ABCL) is a Great Momentum Stock: Should You Buy? - Yahoo Finance Mon, 29 Sep 2025 07
- AbCellera's Q4 revenue led by patent deal; 2025 ends with $700M - Stock Titan ue, 24 Feb 2026 08
- Is ABCELLERA BIOLG (ABCL) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance ue, 30 Sep 2025 07
- AbCellera schedules three healthcare investor conference talks - Stock Titan Wed, 11 Feb 2026 08
- Insider Purchase: Chief Financial Officer of $ABCL Buys 42,600 Shares - Quiver Quantitative Fri, 27 Feb 2026 08
- AbCellera Biologics Inc (ABCL) Down 23% Since Q3 2025 Results - Yahoo Finance hu, 04 Dec 2025 08
- AbCellera (ABCL) Is Up 18.8% After Pivoting To Clinical Stage And Filing Share Offering - simplywall.st Sat, 28 Feb 2026 08
- AbCellera (NASDAQ: ABCL) 2025 results show revenue jump and strong liquidity - Stock Titan ue, 24 Feb 2026 08
- Insider Purchase: 10% owner at $ABCL Buys 38,000 Shares - Quiver Quantitative Mon, 02 Mar 2026 19
- Why AbCellera (ABCL) Is Up 11.5% After Narrowing Losses And Expanding ESOP Share Capacity – And What's Next - Yahoo Finance hu, 26 Feb 2026 08
- Reassessing AbCellera Biologics (ABCL) After A Sharp 16.8% Weekly Share Price Drop - Yahoo Finance hu, 29 Jan 2026 08
- AbCellera Biologics Inc. (ABCL) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance ue, 24 Feb 2026 08
- $ABCL stock is up 3% today. Here's what we see in our data. - Quiver Quantitative Fri, 28 Nov 2025 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 42600 | 145692 | — | Purchase at price 3.42 per share. | BOOTH ANDREW | Chief Financial Officer | — | 2026-02-27 00:00:00 | D |
| 1 | 38000 | 130720 | — | Purchase at price 3.44 per share. | THERMOPYLAE HOLDINGS, LTD. | Beneficial Owner of more than 10% of a Class of Security | — | 2026-02-27 00:00:00 | D |
| 2 | 177457 | 580284 | — | Purchase at price 3.27 per share. | THERMOPYLAE HOLDINGS, LTD. | Beneficial Owner of more than 10% of a Class of Security | — | 2026-02-26 00:00:00 | D |
| 3 | 225000 | — | — | Stock Gift at price 0.00 per share. | THERMOPYLAE HOLDINGS, LTD. | Beneficial Owner of more than 10% of a Class of Security | — | 2025-12-18 00:00:00 | D |
| 4 | 50000 | 178460 | — | Purchase at price 3.57 per share. | MONTALBANO JOHN S. | Director | — | 2025-11-26 00:00:00 | D |
| 5 | 343631 | 742243 | — | Purchase at price 2.16 per share. | THERMOPYLAE HOLDINGS, LTD. | Beneficial Owner of more than 10% of a Class of Security | — | 2025-03-11 00:00:00 | D |
| 6 | 25000 | 57500 | — | Purchase at price 2.30 per share. | MONTALBANO JOHN S. | Director | — | 2025-03-10 00:00:00 | D |
| 7 | 60000 | 140568 | — | Purchase at price 2.34 per share. | MONTALBANO JOHN S. | Director | — | 2025-03-06 00:00:00 | D |
| 8 | 286000 | — | — | Stock Gift at price 0.00 per share. | THERMOPYLAE HOLDINGS, LTD. | Beneficial Owner of more than 10% of a Class of Security | — | 2024-12-04 00:00:00 | D |
| 9 | 56125 | 151538 | — | Conversion of Exercise of derivative security at price 2.70 per share. | HANSEN CARL L.G. | Chief Executive Officer | — | 2024-11-25 00:00:00 | D |
Financials
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.18 | 0.19 | 0.16 | 0.34 |
| NormalizedEBITDA | -174.39M | -204.15M | -192.16M | 260.17M |
| TotalUnusualItems | -855.00K | |||
| TotalUnusualItemsExcludingGoodwill | -855.00K | |||
| NetIncomeFromContinuingOperationNetMinorityInterest | -146.41M | -162.86M | -146.40M | 158.52M |
| ReconciledDepreciation | 28.82M | 97.00M | 30.89M | 33.10M |
| ReconciledCostOfRevenue | 0.00 | 0.00 | 61.18M | 42.72M |
| EBITDA | -174.39M | -204.15M | -192.16M | 260.17M |
| EBIT | -203.21M | -301.15M | -223.05M | 227.06M |
| NetInterestIncome | 28.33M | 38.47M | 42.25M | 16.08M |
| InterestExpense | 4.04M | 5.22M | ||
| InterestIncome | 28.33M | 38.47M | 42.25M | 16.08M |
| NormalizedIncome | -146.41M | -162.86M | -146.40M | 158.52M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -146.41M | -162.86M | -146.40M | 158.52M |
| TotalExpenses | 278.34M | 329.98M | 261.08M | 258.36M |
| TotalOperatingIncomeAsReported | -217.10M | -314.77M | -237.21M | 216.51M |
| DilutedAverageShares | 298.71M | 294.33M | 289.17M | 314.83M |
| BasicAverageShares | 298.71M | 294.33M | 289.17M | 285.06M |
| DilutedEPS | -0.49 | -0.55 | -0.51 | 0.50 |
| BasicEPS | -0.49 | -0.55 | -0.51 | 0.56 |
| DilutedNIAvailtoComStockholders | -146.41M | -162.86M | -146.40M | 158.52M |
| NetIncomeCommonStockholders | -146.41M | -162.86M | -146.40M | 158.52M |
| OtherunderPreferredStockDividend | 0.00 | 0.00 | ||
| NetIncome | -146.41M | -162.86M | -146.40M | 158.52M |
| NetIncomeIncludingNoncontrollingInterests | -146.41M | -162.86M | -146.40M | 158.52M |
| NetIncomeContinuousOperations | -146.41M | -162.86M | -146.40M | 158.52M |
| TaxProvision | -31.18M | -37.54M | -27.63M | 80.58M |
| PretaxIncome | -177.59M | -200.40M | -174.03M | 239.10M |
| OtherIncomeExpense | -2.71M | 62.28M | 6.78M | -4.04M |
| OtherNonOperatingIncomeExpenses | -2.71M | 62.28M | 6.78M | -4.04M |
| GainOnSaleOfSecurity | -855.00K | |||
| NetNonOperatingInterestIncomeExpense | 28.33M | 38.47M | 42.25M | 16.08M |
| InterestExpenseNonOperating | 4.04M | 5.22M | ||
| InterestIncomeNonOperating | 28.33M | 38.47M | 42.25M | 16.08M |
| OperatingIncome | -203.21M | -301.15M | -223.05M | 227.06M |
| OperatingExpense | 278.34M | 329.98M | 261.08M | 191.92M |
| OtherOperatingExpenses | -13.89M | -13.62M | -14.15M | -10.55M |
| DepreciationAmortizationDepletionIncomeStatement | 22.17M | 90.85M | 24.39M | 27.84M |
| DepreciationAndAmortizationInIncomeStatement | 22.17M | 90.85M | 24.39M | 27.84M |
| DepreciationIncomeStatement | 27.84M | 14.45M | ||
| ResearchAndDevelopment | 186.83M | 167.26M | 175.66M | 107.88M |
| SellingGeneralAndAdministration | 83.23M | 85.49M | 75.18M | 66.75M |
| SellingAndMarketingExpense | 12.78M | 14.18M | 11.27M | 6.91M |
| GeneralAndAdministrativeExpense | 72.71M | 61.00M | 55.48M | 41.85M |
| OtherGandA | 72.71M | 61.00M | 55.48M | 41.85M |
| GrossProfit | 28.83M | 38.02M | 418.99M | 329.69M |
| CostOfRevenue | 0.00 | 0.00 | 66.44M | 45.52M |
| TotalRevenue | 75.13M | 28.83M | 38.02M | 485.42M |
| OperatingRevenue | 75.13M | 28.83M | 38.02M | 485.42M |
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 300.60M | 295.76M | 290.82M | 286.85M |
| ShareIssued | 300.60M | 295.76M | 290.82M | 286.85M |
| TotalDebt | 143.22M | 65.36M | 77.38M | 82.26M |
| TangibleBookValue | 880.72M | 966.16M | 984.09M | 1.05B |
| InvestedCapital | 966.90M | 1.06B | 1.15B | 1.23B |
| WorkingCapital | 663.92M | 674.76M | 752.97M | 907.17M |
| NetTangibleAssets | 880.72M | 966.16M | 984.09M | 1.05B |
| CapitalLeaseObligations | 143.22M | 65.36M | 77.38M | 82.26M |
| CommonStockEquity | 966.90M | 1.06B | 1.15B | 1.23B |
| TotalCapitalization | 966.90M | 1.06B | 1.15B | 1.23B |
| TotalEquityGrossMinorityInterest | 966.90M | 1.06B | 1.15B | 1.23B |
| StockholdersEquity | 966.90M | 1.06B | 1.15B | 1.23B |
| GainsLossesNotAffectingRetainedEarnings | -4.23M | -4.38M | -1.72M | -1.39M |
| OtherEquityAdjustments | -4.23M | -4.38M | -1.72M | -1.39M |
| RetainedEarnings | -29.48M | 116.93M | 279.79M | 426.19M |
| AdditionalPaidInCapital | 198.28M | 166.36M | 121.05M | 74.12M |
| CapitalStock | 802.34M | 777.17M | 753.20M | 734.37M |
| CommonStock | 802.34M | 777.17M | 753.20M | 734.37M |
| TotalLiabilitiesNetMinorityInterest | 390.05M | 304.47M | 335.78M | 307.63M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 325.74M | 227.86M | 216.76M | 189.31M |
| OtherNonCurrentLiabilities | 4.77M | 1.47M | 5.91M | 3.09M |
| TradeandOtherPayablesNonCurrent | 0.00 | 4.91M | 16.05M | 35.89M |
| NonCurrentDeferredLiabilities | 183.57M | 165.65M | 134.72M | 93.50M |
| NonCurrentDeferredRevenue | 174.45M | 155.59M | 104.11M | 60.32M |
| NonCurrentDeferredTaxesLiabilities | 9.12M | 10.05M | 30.61M | 33.18M |
| LongTermDebtAndCapitalLeaseObligation | 137.40M | 60.74M | 71.22M | 76.67M |
| LongTermCapitalLeaseObligation | 137.40M | 60.74M | 71.22M | 76.67M |
| CurrentLiabilities | 64.31M | 76.61M | 119.01M | 118.32M |
| OtherCurrentLiabilities | 4.93M | |||
| CurrentDeferredLiabilities | 22.51M | 21.18M | 26.07M | 27.90M |
| CurrentDeferredRevenue | 22.51M | 21.18M | 26.07M | 27.90M |
| CurrentDebtAndCapitalLeaseObligation | 5.82M | 4.62M | 6.16M | 5.58M |
| CurrentCapitalLeaseObligation | 5.82M | 4.62M | 6.16M | 5.58M |
| PayablesAndAccruedExpenses | 35.98M | 50.81M | 86.78M | 84.84M |
| CurrentAccruedExpenses | 10.76M | 8.38M | 7.71M | 6.45M |
| Payables | 25.23M | 42.44M | 79.08M | 78.39M |
| OtherPayable | 8.09M | 50.48M | 63.56M | 45.44M |
| TotalTaxPayable | 0.00 | 35.68M | ||
| IncomeTaxPayable | 0.00 | 35.68M | ||
| AccountsPayable | 25.23M | 34.35M | 28.60M | 14.83M |
| TotalAssets | 1.36B | 1.36B | 1.49B | 1.54B |
| TotalNonCurrentAssets | 628.72M | 609.18M | 616.11M | 515.42M |
| OtherNonCurrentAssets | 51.95M | 96.54M | 94.24M | 46.33M |
| NonCurrentPrepaidAssets | 16.47M | |||
| NonCurrentDeferredAssets | 7.41M | |||
| NonCurrentDeferredTaxesAssets | 7.41M | |||
| InvestmentsAndAdvances | 62.58M | 82.30M | 65.94M | 72.52M |
| OtherInvestments | 6.76M | |||
| LongTermEquityInvestment | 62.58M | 82.30M | 65.94M | 72.52M |
| GoodwillAndOtherIntangibleAssets | 86.19M | 89.92M | 168.23M | 179.31M |
| OtherIntangibleAssets | 38.38M | 42.11M | 120.42M | 131.50M |
| Goodwill | 47.81M | 47.81M | 47.81M | 47.81M |
| NetPPE | 428.00M | 340.43M | 287.70M | 217.25M |
| AccumulatedDepreciation | -57.61M | -39.72M | -30.61M | -18.48M |
| GrossPPE | 485.62M | 380.15M | 318.30M | 235.73M |
| Leases | 122.89M | 73.94M | 40.57M | 22.75M |
| OtherProperties | 239.05M | 150.94M | 147.01M | 122.09M |
| MachineryFurnitureEquipment | 3.52M | 8.30M | 7.84M | |
| BuildingsAndImprovements | 193.16M | 52.91M | 43.95M | 11.36M |
| LandAndImprovements | 53.41M | 53.41M | 53.41M | 53.41M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 728.23M | 751.37M | 871.99M | 1.03B |
| OtherCurrentAssets | 9.67M | 8.63M | 22.02M | 9.06M |
| RestrictedCash | 25.00M | 25.00M | 25.00M | 25.00M |
| PrepaidAssets | 9.06M | 5.29M | ||
| Inventory | 6.34M | 0.00 | 1.11M | 1.53M |
| RawMaterials | 6.34M | 0.00 | 1.11M | 1.53M |
| Receivables | 153.40M | 92.13M | 64.38M | 103.41M |
| TaxesReceivable | 55.70M | 26.53M | 33.79M | 64.82M |
| LoansReceivable | 39.41M | 31.98M | 0.00 | |
| AccountsReceivable | 58.29M | 33.62M | 30.59M | 38.59M |
| CashCashEquivalentsAndShortTermInvestments | 533.83M | 625.61M | 760.59M | 886.49M |
| OtherShortTermInvestments | 405.31M | 469.29M | 627.26M | 499.95M |
| CashAndCashEquivalents | 128.51M | 156.32M | 133.32M | 386.54M |
| CashEquivalents | 29.30M | 29.20M | ||
| CashFinancial | 99.30M | 127.10M |
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -174.07M | -186.95M | -121.38M | 204.70M |
| RepaymentOfDebt | -323.00K | -1.82M | ||
| IssuanceOfDebt | 11.59M | 2.75M | 5.49M | |
| IssuanceOfCapitalStock | 0.00 | 0.00 | ||
| CapitalExpenditure | -42.77M | -78.40M | -77.51M | -72.66M |
| EndCashPosition | 155.25M | 183.62M | 160.61M | 414.65M |
| BeginningCashPosition | 183.62M | 160.61M | 414.65M | 501.14M |
| EffectOfExchangeRateChanges | 1.10M | -2.62M | 589.00K | -9.60M |
| ChangesInCash | -29.46M | 25.62M | -254.63M | -76.89M |
| FinancingCashFlow | 14.08M | 12.77M | 10.36M | -1.63M |
| CashFlowFromContinuingFinancingActivities | 14.08M | 12.77M | 10.36M | -1.63M |
| NetOtherFinancingCharges | 14.08M | 12.77M | 10.36M | -1.63M |
| ProceedsFromStockOptionExercised | 4.62M | |||
| NetPreferredStockIssuance | 0.00 | 0.00 | ||
| PreferredStockIssuance | 0.00 | 0.00 | ||
| NetCommonStockIssuance | 0.00 | 0.00 | ||
| CommonStockIssuance | 0.00 | 0.00 | ||
| NetIssuancePaymentsOfDebt | 11.59M | 2.43M | 5.49M | |
| NetShortTermDebtIssuance | 0.00 | |||
| NetLongTermDebtIssuance | 11.59M | 2.43M | 5.49M | |
| LongTermDebtPayments | -323.00K | -1.82M | ||
| LongTermDebtIssuance | 11.59M | 2.75M | 5.49M | |
| InvestingCashFlow | 87.75M | 121.41M | -221.11M | -352.62M |
| CashFlowFromContinuingInvestingActivities | 87.75M | 121.41M | -221.11M | -352.62M |
| NetOtherInvestingChanges | 54.61M | 35.71M | 25.31M | 16.43M |
| DividendsReceivedCFI | 30.11M | 0.00 | 0.00 | |
| NetInvestmentPurchaseAndSale | 52.94M | 183.72M | -155.22M | -270.72M |
| SaleOfInvestment | 506.07M | 948.81M | 910.94M | 510.63M |
| PurchaseOfInvestment | -453.14M | -765.09M | -1.07B | -781.35M |
| NetBusinessPurchaseAndSale | -7.14M | -19.63M | -13.69M | -25.68M |
| PurchaseOfBusiness | -7.14M | -19.63M | -13.69M | -25.68M |
| NetIntangiblesPurchaseAndSale | 0.00 | -560.00K | -2.00M | 0.00 |
| PurchaseOfIntangibles | 0.00 | -560.00K | -2.00M | 0.00 |
| NetPPEPurchaseAndSale | -42.77M | -78.40M | -76.95M | -70.66M |
| PurchaseOfPPE | -42.77M | -78.40M | -76.95M | -70.66M |
| OperatingCashFlow | -131.29M | -108.56M | -43.88M | 277.36M |
| CashFlowFromContinuingOperatingActivities | -131.29M | -108.56M | -43.88M | 277.36M |
| ChangeInWorkingCapital | -70.69M | -25.84M | 13.22M | 29.82M |
| ChangeInOtherWorkingCapital | -35.68M | 32.69M | 56.01M | -73.16M |
| ChangeInOtherCurrentLiabilities | -3.06M | -778.00K | ||
| ChangeInOtherCurrentAssets | 17.15M | 5.95M | 8.98M | -1.38M |
| ChangeInPayablesAndAccruedExpense | 3.46M | 10.63M | -15.10M | -2.09M |
| ChangeInAccruedExpense | -3.16M | -4.64M | ||
| ChangeInPayable | -15.10M | -87.54M | -3.24M | |
| ChangeInAccountPayable | -15.10M | 1.07M | -3.24M | |
| ChangeInTaxPayable | -88.61M | -13.53M | ||
| ChangeInIncomeTaxPayable | -88.61M | -13.53M | ||
| ChangeInReceivables | -55.62M | -75.12M | -36.66M | 106.46M |
| ChangesInAccountReceivables | -55.62M | -75.12M | -45.93M | -22.71M |
| OtherNonCashItems | 1.20M | -84.44M | -5.78M | 6.43M |
| StockBasedCompensation | 55.79M | 67.58M | 64.18M | 49.48M |
| DeferredTax | 1.96M | -2.11M | -2.02M | |
| DeferredIncomeTax | 1.96M | -2.11M | -2.02M | |
| DepreciationAmortizationDepletion | 28.82M | 97.00M | 30.89M | 33.10M |
| DepreciationAndAmortization | 28.82M | 97.00M | 30.89M | 33.10M |
| AmortizationCashFlow | 3.73M | 78.31M | 11.64M | 18.89M |
| AmortizationOfIntangibles | 3.73M | 78.31M | 11.64M | 18.89M |
| Depreciation | 25.09M | 18.69M | 19.26M | 14.21M |
| NetIncomeFromContinuingOperations | -146.41M | -162.86M | -146.40M | 158.52M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for ABCL
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|